Zydus launches world’s first biosimilar to Opdivo
India’s Zydus Lifesciences (BOM: 532321), an innovation-led life-sciences company with an international presence, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha, reinforcing the company’s growing capability in advanced biologics and immuno-oncology.
Tishtha will be available in 100mg and 40mg dosages priced at 28,950 rupees (~$316) and 13,950 rupees respectively. The prices are approximately a quarter of the reference drug, Bristol Myers Squibb’s (NYSE: BMY) Opdivo. Global sales of Opdivo in the third quarter of 2025 were $2.5 billion.
This will improve affordability and reduce the overall treatment burden for patients. The two strength portfolio enables oncologists to optimize dosing and minimize wastage – a key driver of treatment economics in immunotherapy, the company noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze